Erica Weinstein
Founder at Profound Therapeutics
Erica Weinstein active positions
Companies | Position | Start | End |
---|---|---|---|
Flagship Pioneering
Flagship Pioneering Investment ManagersFinance Flagship Pioneering (Flagship Pioneering) is a venture capital firm founded in 1982 by Ed M Kania and Noubar B Afeyan. The firm is headquartered in Cambridge, Massachusetts. | Private Equity Investor | 2014-12-31 | - |
Profound Therapeutics
Profound Therapeutics Pharmaceuticals: OtherHealth Technology Profound Therapeutics is a company that is focused on discovering new medicines by expanding the human proteome. The company is based in Cambridge, MA. The company uses their platform, Profoundry, to identify and validate proteins and understand their therapeutic potential. This results in a growing database of novel proteins and their roles in health and disease. The company was founded in 2020 by Avak Kahvejian, who has been the CEO since then. | Founder | 2019-12-31 | - |
Career history of Erica Weinstein
Training of Erica Weinstein
Icahn School of Medicine at Mount Sinai | Doctorate Degree |
Emory University | Undergraduate Degree |
Statistics
International
United States | 5 |
Operational
Private Equity Investor | 1 |
Doctorate Degree | 1 |
Undergraduate Degree | 1 |
Sectoral
Consumer Services | 3 |
Finance | 2 |
Health Technology | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Private companies | 2 |
---|---|
Flagship Pioneering
Flagship Pioneering Investment ManagersFinance Flagship Pioneering (Flagship Pioneering) is a venture capital firm founded in 1982 by Ed M Kania and Noubar B Afeyan. The firm is headquartered in Cambridge, Massachusetts. | Finance |
Profound Therapeutics
Profound Therapeutics Pharmaceuticals: OtherHealth Technology Profound Therapeutics is a company that is focused on discovering new medicines by expanding the human proteome. The company is based in Cambridge, MA. The company uses their platform, Profoundry, to identify and validate proteins and understand their therapeutic potential. This results in a growing database of novel proteins and their roles in health and disease. The company was founded in 2020 by Avak Kahvejian, who has been the CEO since then. | Health Technology |
- Stock Market
- Insiders
- Erica Weinstein
- Experience